This site is intended for US healthcare
professionals only.

Ohtuvayre was studied across a wide range of patient types1

You may see patients similar to those below in your practice. For patients with persistent symptoms of COPD, a novel therapy could offer an effective treatment option.1,2

Back to top
Maureen, Age 65
Jackson, Age 66
Jane, Age 62
Dave, Age 57
Back to top
Maureen, Age 65

Working long hours as a small business owner, Maureen used to find freedom on the trails, but her COPD symptoms have caused her to abandon her favorite pastime.

Maureen suffers from dyspnea with exertion and suffers sudden coughing fits that can last minutes.

Currently on combined bronchodilator/ICS therapy.

Post-bronchodilator FEV1 is 49% of predicted.

Recent history of exacerbation requiring hospitalization.

FEV1 = forced expiratory volume in one second; ICS = inhaled corticosteroids.

Jackson, Age 66

Jackson is a high school history teacher approaching retirement with a longstanding tradition of never calling out or missing a class—until recently, that is, as his persistent dyspnea has started to keep him at home and out of the classroom.

Currently on nebulized bronchodilator therapy.

Post-bronchodilator FEV1 is 53% of predicted.

Symptoms are worsening and he recently required a round of antibiotics.

Has type 2 diabetes.

FEV1 = forced expiratory volume in one second

Jane, Age 62

Jane is always there for her growing family. Or, at least, she tries to be. As of late, her coughing fits and chronic bronchitis have caused her to be absent from her grandkids’ events like piano recitals and plays.

Has some concerns about ICS therapy.

Post-bronchodilator FEV1 is 53% of predicted.

Is a former smoker.

Has chronic bronchitis.

FEV1 = forced expiratory volume in one second; ICS = inhaled corticosteroids.

Dave, Age 57

Dave is a tour guide at a local art museum whose passion used to drive him to talk for hours. Now, he’s sharing less and less, encumbered by breathlessness and COPD symptoms.

Struggles with persistent dyspnea and has switched medications many times.

Post-bronchodilator FEV1 is 45% of predicted.

Is a former smoker.

Has diabetes and coronary artery disease.

FEV1 = forced expiratory volume in one second.

A first-in-class and truly novel way to improve lung function in patients with symptomatic COPD1,2

See the impact of Ohtuvayre on
lung function in clinical studies.

Take a look at the safety profile
of Ohtuvayre.

Warnings and Precautions:

Acute Episodes of Bronchospasm Ohtuvayre should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.

Paradoxical Bronchospasm As with other inhaled medicines, Ohtuvayre may produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Ohtuvayre, it should be treated immediately with an inhaled, short-acting bronchodilator. Ohtuvayre should be discontinued immediately and alternative therapy should be instituted.

Psychiatric Events Including Suicidality Before initiating treatment with Ohtuvayre, healthcare providers should carefully weigh the risk and benefits of treatment with Ohtuvayre in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and if such changes occur to contact their healthcare provider. Healthcare providers should carefully evaluate the risks and benefits of continuing treatment with Ohtuvayre if such events occur.

Treatment with Ohtuvayre is associated with an increase in psychiatric adverse reactions. Psychiatric events including suicide-related adverse reactions were reported in clinical studies in patients who received Ohtuvayre (1 suicide attempt and 1 suicide). Additionally, the most commonly reported psychiatric adverse reactions in the pooled 24-week safety population were insomnia (6 patients [0.6%] Ohtuvayre 3 mg; 2 patients [0.3%] placebo), and anxiety (2 patients [0.2%] Ohtuvayre 3 mg; 1 patient [0.2%] placebo). Depression-related reactions including depression, major depression, and adjustment disorder with depressed mood occurred in 4 patients [0.4%] receiving Ohtuvayre and no patients receiving placebo.

Adverse Reactions: The most common adverse reactions ≥1% in Ohtuvayre and greater than placebo in the pooled population were back pain 1.8%, hypertension 1.7%, urinary tract infection 1.3%, and diarrhea 1.0%.

These are not all of the possible risks associated with Ohtuvayre. Please see Full Prescribing Information for Ohtuvayre.

To report suspected adverse reactions, contact Verona Pharma, Inc. at
1-888-672-0371 or FDA at
1-800-FDA-1088 or
www.fda.gov/medwatch.

References:
1. Ohtuvayre™ (ensifentrine). Prescribing Information. Raleigh, NC: Verona Pharma plc; 2024. 2. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416.